Mark McCamish
Director/Board Member at AVADEL PHARMACEUTICALS PLC
Net worth: 1 M $ as of 2024-03-30
Profile
Mark A.
McCamish is currently serving as the President, Chief Executive Officer & Director at IconOVir Bio, Inc. He is also an Independent Director at Avadel Pharmaceuticals Plc and Rafael Holdings, Inc. Previously, Dr. McCamish held the positions of President, Chief Executive Officer & Director at Forty Seven, Inc. from 2017 to 2020.
He was also a Director at Abbott Laboratories in 1997.
Additionally, he served as an Independent Director at Vincerx Pharma, Inc. from 2020 to 2021.
Dr. McCamish has a background in academia, having worked as a Professor at The Ohio State University and the University of California, Davis.
He also held the role of Chief Medical Officer & Senior Vice President at PDL BioPharma, Inc. from 2007 to 2008.
In terms of education, Dr. McCamish obtained a doctorate degree from The Pennsylvania State University in 1980.
He also holds undergraduate and graduate degrees from the University of California, Santa Barbara, and a doctorate degree from the David Geffen School of Medicine.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-12-27 | 67,025 ( 0.04% ) | 1 M $ | 2024-03-30 | |
2024-01-04 | 60,241 ( 0.25% ) | 103 615 $ | 2024-03-30 |
Mark McCamish active positions
Companies | Position | Start |
---|---|---|
AVADEL PHARMACEUTICALS PLC | Director/Board Member | 2019-12-04 |
RAFAEL HOLDINGS, INC. | Director/Board Member | 2021-06-13 |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Chief Executive Officer | 2020-10-31 |
Former positions of Mark McCamish
Companies | Position | End |
---|---|---|
VINCERX PHARMA, INC. | Director/Board Member | 2021-05-12 |
FORTY SEVEN, INC. | Chief Executive Officer | 2020-04-06 |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | 2017-03-31 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Chief Tech/Sci/R&D Officer | 2009-03-31 |
PDL BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 2008-11-30 |
Training of Mark McCamish
The Pennsylvania State University | Doctorate Degree |
University of California, Santa Barbara | Graduate Degree |
David Geffen School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
ABBOTT LABORATORIES | Health Technology |
AVADEL PHARMACEUTICALS PLC | Health Technology |
RAFAEL HOLDINGS, INC. | Finance |
VINCERX PHARMA, INC. | Health Technology |
Private companies | 6 |
---|---|
Perlegen Sciences, Inc.
Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Perlegen Sciences, Inc. discovers and develops drugs. Its product pipeline consists of targeted drug candidates addressing type II diabetes and dyslipidemia markets. The company's products include PGX-510 and PGX-520. It operates in the United States, European Union, and Japan. Perlegen Sciences was co-founded by Brad A. Margus, David R. Cox, and Stephen P. A. Fodor in 2000 and is headquartered in Mountain View, CA | Retail Trade |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Health Technology |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Forty Seven, Inc.
Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Health Technology |
- Stock Market
- Insiders
- Mark McCamish